Minoru Yamamoto

This inventor holds 20 USPTO granted patents, plus 1 CIPO patent and 12 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Santen Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corporation. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Minoru Yamamoto. Retrieved from https://idiyas.com/inventor/minoru-yamamoto-bwftnj6b

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20

% Patents Active = 10.0

CIPO Patents = 1

EPO Patents = 12 (Patent Applications = 5)

Average Co-Inventor Count = 6.7

ph-index = 2

Forward Citations = 17(Granted Patents)

Company Filing History:

19 out of 282

Santen Pharmaceutical Co., Ltd.

patents

1 out of 3

Ayumi Pharmaceutical Corporation

patents

Years Active: 2009-2021

Loading Chart...

Areas of Expertise:

Glucocorticoid Receptor

Heterocyclic Compounds

Indole Derivative

Pyrrole Derivative

Cyclic Compounds

Thiophenediamine

Tetrahydroquinoxaline

Pyridinecarboxylic Acid

Urea Structure

4-Pyridylalkylthio

Aminocarbonyl Group

IB Kinase Inhibitory

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11186588 - 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative (2021-11-30),

2. 8975256 - 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity (2015-03-10),

3. 8551991 - 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity (2013-10-08),

4. 8518973 - Compounds having 4-pyridylalkylthio group as a substituent (2013-08-27),

5. 8507485 - Cyclic compound having pyrimidinylalkylthio group (2013-08-13),

6. 8445529 - Indole derivative having, carbamoyl group, ureido group and substituted oxy group (2013-05-21),

7. 8420635 - Method for preventing or treating a glucocorticoid receptor-related disease (2013-04-16),

8. 8288380 - Thiophenediamine derivative having urea structure (2012-10-16),

9. 8207194 - Compounds having a 4-pyridylalkylthio group as a substituent (2012-06-26),

10. 8198271 - Thiophenediamine derivative having urea structure (2012-06-12),

11. 8193237 - Indole derivative having IκB kinase β inhibitory activity (2012-06-05),

12. 8088817 - Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent (2012-01-03),

13. 8076332 - N- (2-aminophenyl) benzamide derivative having urea structure (2011-12-13),

14. 8017775 - 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity (2011-09-13),

15. 8012972 - Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure (2011-09-06),

Sure! Here is the article about inventor Minoru Yamamoto:

Title: Innovator Spotlight: Minoru Yamamoto - Pioneering Medicinal Chemist

Introduction:

Minoru Yamamoto, a prolific inventor hailing from Ikoma, Japan, has made significant contributions to the field of medicinal chemistry with his groundbreaking patents. With an impressive portfolio of 20 patents to his name, Yamamoto has been at the forefront of developing innovative compounds for various medical applications.

Latest Patents:

Yamamoto's recent patents showcase his expertise in designing novel compounds with specific pharmacological activities. One notable patent is the 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative, which demonstrates BRD4 inhibitory activity. This compound holds immense potential as a prophylactic and therapeutic agent for BRD4-associated diseases. Additionally, his patent on 1,2,3,4-tetrahydroquinoxaline compounds highlights his proficiency in developing molecules with glucocorticoid receptor binding activity.

Career Highlights:

Throughout his career, Yamamoto has lent his expertise to renowned companies such as Santen Pharmaceutical Co., Ltd. and Ayumi Pharmaceutical Corporation. His tenure at these organizations has been marked by a dedication to innovation and a commitment to advancing the field of medicinal chemistry. Yamamoto's contributions have played a pivotal role in shaping the landscape of pharmaceutical research and development.

Collaborations:

Yamamoto has had the privilege of collaborating with esteemed colleagues such as Kenji Kawashima and Hisashi Tajima. Together, they have worked diligently to explore new avenues in drug discovery and development, fostering a culture of innovation and excellence in their professional endeavors.

Conclusion:

In conclusion, Minoru Yamamoto stands as a shining example of an inventive mind in the realm of medicinal chemistry. His patents reflect a deep understanding of pharmacological mechanisms and a relentless pursuit of novel solutions to complex medical challenges. Yamamoto's work continues to inspire and drive progress in the field, underscoring his status as a visionary inventor shaping the future of healthcare.

Profile summary based on public USPTO records.